MHRA allows HAE patients early access to berotralstat
The oral, once-daily therapy is designed to prevent attacks and reduce burden of therapy
Read More
Tag: hereditary angioedema
Shire receives EU approval for Takhzyro
Shire has announced that the European Commission has approved its hereditary angioedema (HAE) drug Takhzyro.
Read More
Shire’s lanadelumab shown to significantly cut HAE attacks
Shire says it presented data showing that its experimental drug lanadelumab provides a significant and clinically meaningful reduction of hereditary angioedema (HAE) attacks.
Read More
Shire’s HAE drug Takhzyro gets green light in the US
Shire’s Takhzyro has been approved in the US for the prevention of attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
Read More
Speedy EU review for Shire’s lanadelumab
European regulators will undertake an accelerated assessment of Shire’s hereditary angioedema (HAE) drug lanadelumab.
Read More
US nod for CSL Behring’s HAE prevention therapy
US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
